The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease
Open accessAbstract
OBJECTIVES The objective of this study was to determine whether colchicine 0.5 mg/day can reduce the risk of cardiovascular events in patients with clinically stable coronary disease. BACKGROUND The presence of activated neutrophils in culprit atherosclerotic plaques of patients with unstable coronary disease raises the possibility that inhibition of neutrophil function with colchicine may reduce the risk of plaque instability and thereby improve clinical outcomes in patients with stable coronary disease. METHODS In a clinical trial with a prospective, randomized, observer-blinded endpoint design, 532 patients with stable coronary disease receiving aspirin and/or clopidogrel (93%) and statins (95%) were randomly assigned colchicine 0.5 mg/day or no colchicine and followed for a median of 3 years. The primary outcome was the composite incidence of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke. The primary analysis was by intention-to-treat. RESULTS The primary outcome occurred in 15 of 282 patients (5.3%) who received colchicine and 40 of 250 patients (16.0%) assigned no colchicine (hazard ratio: 0.33; 95% confidence interval [CI] 0.18 to 0.59; p < 0.001; number needed to treat: 11). In a pre-specified secondary on-treatment analysis that excluded 32 patients (11%) assigned to colchicine who withdrew within 30 days due to intestinal intolerance and a further 7 patients (2%) who did not start treatment, the primary outcome occurred in 4.5% versus 16.0% (hazard ratio: 0.29; 95% CI: 0.15 to 0.56; p < 0.001). CONCLUSIONS Colchicine 0.5 mg/day administered in addition to statins and other standard secondary prevention therapies appeared effective for the prevention of cardiovascular events in patients with stable coronary disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., White, H. D., TASK FORCE MEMBERS: Chairpersons: Kristian Thygesen (Denmark), J. S. A. (., Biomarker Group: Allan S. Jaffe, C. (., ECG Group: Bernard Chaitman, C.-O. (., Imaging Group: Richard Underwood, C. (., Intervention Group: Jean-Pierre Bassand, C.-O. (., Clinical Investigation Group: Paul W. Armstrong, C. (., Global Perspective Group: Philip A. Poole-Wilson, C. (., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.187397 · Cited by 4,230
Falk, E., Shah, P. K., & Fuster, V. (1995) · Circulation · doi:10.1161/01.cir.92.3.657 · Cited by 3,536
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,276
Thygesen, K. A. (2007) · Circulation · Cited by 3,126
Universal Definition of Myocardial Infarction
Thygesen, K., Alpert, J. S., & White, H. D. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.09.011 · Cited by 1,618
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Neutrophil Infiltration of Culprit Lesions in Acute Coronary Syndromes
Naruko, T., Ueda, M., Haze, K., van der Wal, A. C., van der Loos, C. M., Itoh, A., Komatsu, R., Ikura, Y., Ogami, M., Shimada, Y., et al. (2002) · Circulation · doi:10.1161/01.cir.0000042674.89762.20 · Cited by 660
Imazio, M., Bobbio, M., Cecchi, E., Demarie, D., Demichelis, B., Pomari, F., Moratti, M., Gaschino, G., Giammaria, M., Ghisio, A., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.542738 · Cited by 614
Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trials
Hansson, L., Hedner, T., & Dahlöf, B. (1992) · Blood Pressure · doi:10.3109/08037059209077502 · Cited by 577
A Classification of Unstable Angina Revisited
Hamm, C. W., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.1.118 · Cited by 394
Cited by
Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty
Ferrucci, L., & Fabbri, E. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0064-2 · Cited by 3,690
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
Colchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Self-citationImmunity and Inflammation in Atherosclerosis
Wolf, D., & Ley, K. (2019) · Circulation Research · doi:10.1161/circresaha.118.313591 · Cited by 1,697
2016 updated EULAR evidence-based recommendations for the management of gout
Richette, P., Doherty, M., Pascual, E., Barskova, V, Becce, F., Castañeda-Sanabria, J., Coyfish, M., Guillo, S., Jansen, T. L., Janssens, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209707 · Cited by 1,681
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001168 · Cited by 1,598
Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy
Libby, P. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1216063 · Cited by 1,262
Low Wang, C. C., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,155
Targeting inflammation in atherosclerosis — from experimental insights to the clinic
Soehnlein, O., & Libby, P. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00198-1 · Cited by 1,019
Ridker, P. M. (2016) · Circulation Research · doi:10.1161/circresaha.115.306656 · Cited by 1,002
Colchicine—Update on mechanisms of action and therapeutic uses
Leung, Y. Y., Yao Hui, L. L., & Kraus, V. B. (2015) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2015.06.013 · Cited by 950
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
The Role of Inflammation in Cardiovascular Disease
Henein, M. Y., Vancheri, S., Longo, G., & Vancheri, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232112906 · Cited by 724
Atherosclerosis and inflammation: overview and updates
Geovanini, G. R., & Libby, P. (2018) · Clinical Science · doi:10.1042/cs20180306 · Cited by 703
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies
Jickling, G. C., Liu, D., Ander, B. P., Stamova, B., Zhan, X., & Sharp, F. R. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.45 · Cited by 644
Targeting Early Atherosclerosis: A Focus on Oxidative Stress and Inflammation
Marchio, P., Guerra-Ojeda, S., Vila, J. M., Aldasoro, M., Victor, V. M., & Mauricio, M. D. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8563845 · Cited by 621
Interleukin-1 Beta as a Target for Atherosclerosis Therapy
Libby, P. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.09.028 · Cited by 619
Gout: An old disease in new perspective – A review
Ragab, G., Elshahaly, M., & Bardin, T. (2017) · Journal of Advanced Research · doi:10.1016/j.jare.2017.04.008 · Cited by 599
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · Circulation · doi:10.1161/cir.0000000000001309 · Cited by 625
Virani, S. S., Newby, L. K., Arnold, S. V., Bittner, V., Brewer, L. C., Demeter, S. H., Dixon, D. L., Fearon, W. F., Hess, B., Johnson, H. M., et al. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.04.003 · Cited by 596
2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes
Rao, S. V., O’Donoghue, M. L., Ruel, M., Rab, T., Tamis-Holland, J. E., Alexander, J. H., Baber, U., Baker, H., Cohen, M. G., Cruz-Ruiz, M., et al. (2025) · JACC · doi:10.1016/j.jacc.2024.11.009 · Cited by 552
Anti-inflammatory therapies for cardiovascular disease
Ridker, P. M., & Luscher, T. F. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu203 · Cited by 550
Inflammation, Immunity, and Infection in Atherothrombosis
Libby, P., Loscalzo, J., Ridker, P. M., Farkouh, M. E., Hsue, P. Y., Fuster, V., Hasan, A. A., & Amar, S. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.08.1043 · Cited by 548
Myocardial ischemia-reperfusion injury and the influence of inflammation
Algoet, M., Janssens, S., Himmelreich, U., Gsell, W., Pusovnik, M., Van den Eynde, J., & Oosterlinck, W. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.02.005 · Cited by 545
Inflammation and its Resolution as Determinants of Acute Coronary Syndromes
Libby, P., Tabas, I., Fredman, G., & Fisher, E. A. (2014) · Circulation Research · doi:10.1161/circresaha.114.302699 · Cited by 521
Ertunc, M. E., & Hotamisligil, G. S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r066514 · Cited by 488
Acute Coronary Syndromes: The Way Forward From Mechanisms to Precision Treatment
Crea, F., & Libby, P. (2017) · Circulation · doi:10.1161/circulationaha.117.029870 · Cited by 476
Inflammation and cardiovascular disease: From mechanisms to therapeutics
Alfaddagh, A., Martin, S. S., Leucker, T. M., Michos, E. D., Blaha, M. J., Lowenstein, C. J., Jones, S. R., & Toth, P. P. (2020) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2020.100130 · Cited by 473
Inflammatory cytokines in atherosclerosis: current therapeutic approaches
Tousoulis, D., Oikonomou, E., Economou, E. K., Crea, F., & Kaski, J. C. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv759 · Cited by 460
Targeting cardiovascular inflammation: next steps in clinical translation
Lawler, P. R., Bhatt, D. L., Godoy, L. C., Lüscher, T. F., Bonow, R. O., Verma, S., & Ridker, P. M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa099 · Cited by 443
Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions
Raggi, P., Genest, J., Giles, J. T., Rayner, K. J., Dwivedi, G., Beanlands, R. S., & Gupta, M. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.07.014 · Cited by 433
Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?
Engelen, S. E., Robinson, A. J. B., Zurke, Y.-X., & Monaco, C. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00668-4 · Cited by 425
Mechanism of Action of Colchicine in the Treatment of Gout
Dalbeth, N., Lauterio, T. J., & Wolfe, H. R. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.07.017 · Cited by 416
Ridker, P. M. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.11.037 · Cited by 414
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial
Tong, D. C., Quinn, S., Nasis, A., Hiew, C., Roberts-Thomson, P., Adams, H., Sriamareswaran, R., Htun, N. M., Wilson, W., Stub, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050771 · Cited by 393
Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
Bardin, T., & Richette, P. (2017) · BMC Medicine · doi:10.1186/s12916-017-0890-9 · Cited by 385
Anti-inflammatory therapies for atherosclerosis
Bäck, M., & Hansson, G. K. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.5 · Cited by 378
Bushnell, C., Kernan, W. N., Sharrief, A. Z., Chaturvedi, S., Cole, J. W., Cornwell, W. K., Cosby-Gaither, C., Doyle, S., Goldstein, L. B., Lennon, O., et al. (2024) · Stroke · doi:10.1161/str.0000000000000475 · Cited by 360
Inflamm-ageing: the role of inflammation in age-dependent cardiovascular disease
Liberale, L., Montecucco, F., Tardif, J.-C., Libby, P., & Camici, G. G. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz961 · Cited by 345
Martínez, G. J., Celermajer, D. S., & Patel, S. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.027 · Cited by 342
Immune Pathways in Etiology, Acute Phase, and Chronic Sequelae of Ischemic Stroke
Endres, M., Moro, M. A., Nolte, C. H., Dames, C., Buckwalter, M. S., & Meisel, A. (2022) · Circulation Research · doi:10.1161/circresaha.121.319994 · Cited by 340
Critical roles of inflammation in atherosclerosis
Moriya, J. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.05.010 · Cited by 339
Wiggins, B. S., Saseen, J. J., Page, R. L., Reed, B. N., Sneed, K., Kostis, J. B., Lanfear, D., Virani, S., & Morris, P. B. (2016) · Circulation · doi:10.1161/cir.0000000000000456 · Cited by 333
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Inflammation in Atherosclerosis—No Longer a Theory
Libby, P. (2021) · Clinical Chemistry · doi:10.1093/clinchem/hvaa275 · Cited by 314
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
Ridker, P. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw024 · Cited by 304
Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome
Vaidya, K., Arnott, C., Martínez, G. J., Ng, B., McCormack, S., Sullivan, D. R., Celermajer, D. S., & Patel, S. (2018) · JACC: Cardiovascular Imaging · doi:10.1016/j.jcmg.2017.08.013 · Cited by 300
Slobodnick, A., Shah, B., Pillinger, M. H., & Krasnokutsky, S. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.12.010 · Cited by 294
From Focal Lipid Storage to Systemic Inflammation
Libby, P., & Hansson, G. K. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.061 · Cited by 288
Martínez, G. J., Robertson, S., Barraclough, J., Xia, Q., Mallat, Z., Bursill, C., Celermajer, D. S., & Patel, S. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002128 · Cited by 283
Anti-Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study
Deftereos, S., Giannopoulos, G., Angelidis, C., Alexopoulos, N., Filippatos, G., Papoutsidakis, N., Sianos, G., Goudevenos, J., Alexopoulos, D., Pyrgakis, V., et al. (2015) · Circulation · doi:10.1161/circulationaha.115.017611 · Cited by 279
Systemic inflammation after stroke: implications for post‐stroke comorbidities
Simats, A., & Liesz, A. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202216269 · Cited by 276
Colchicine in Cardiovascular Disease: In-Depth Review
Deftereos, S. G., Beerkens, F. J., Shah, B., Giannopoulos, G., Vrachatis, D. A., Giotaki, S. G., Siasos, G., Nicolas, J., Arnott, C., Patel, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056171 · Cited by 273
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
“Early data with colchicine—a microtubule inhibitor with NLRP3inhibiting effects—are promising and outcome trials of this agent are underway.(117) In ApoE-deficient mice, the selective NLRP3 inhibitor MCC950 has shown reduced development of atherosclerotic lesions, as well as ICAM and VCAM mRNA expression.”
BackgroundFiolet, A. T. L., Opstal, T. S. J., Mosterd, A., Eikelboom, J. W., Jolly, S. S., Keech, A. C., Kelly, P., Tong, D. C., Layland, J., Nidorf, S. M., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab115 · Cited by 253
Self-citationImmunotherapy for cardiovascular disease
Lutgens, E., Atzler, D., Döring, Y., Duchene, J., Steffens, S., & Weber, C. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz283 · Cited by 192
Deftereos, S., Giannopoulos, G., Papoutsidakis, N., Panagopoulou, V., Kossyvakis, C., Raisakis, K., Cleman, M. W., & Stefanadis, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.08.726 · Cited by 161
Novel antiatherosclerotic therapies
Libby, P., & Everett, B. M. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.118.310958 · Cited by 145
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Kraler, S., Libby, P., Evans, P. C., Akhmedov, A., Schmiady, M. O., Reinehr, M., Camici, G. G., & Lüscher, T. F. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.316256 · Cited by 65
Inflammation and thrombosis – testing the hypothesis with anti- inflammatory drug trials
D’Ugo, E., Libby, P., & De Caterina, R. (2016) · Thrombosis and Haemostasis · doi:10.1160/th16-03-0246 · Cited by 54
Masson, W., Lobo, M., Barbagelata, L., Lavalle-Cobo, A., & Molinero, G. (2021) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2021.06.001 · Cited by 17
Metadata
- Authors
- Nidorf, S. M., Eikelboom, J. W., Budgeon, C. A., & Thompson, P. L.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 61
- Issue
- 4
- Pages
- 404-410
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2113978145
- Cited by
- 1,054
- References
- 18
- FWCI
- 16.69
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.